No NCE Decision Yet; More Pressure On AMRN Expected
- On Friday, the FDA updated its Orange Book listing of key patents and regulatory exclusivity designations for brand drugs and once again, no decision was … Continue Reading
Read nowAuthor Archives: David Moskowitz
Sell DVAX Despite Analysts’ Prayers; Reconsider Closer To Cash Value
Most Popular - While shares of Dynavax Technologies (DVAX) were crushed Friday morning due to Thursday’s negative FDA Panel vote on lead candidate Heplisav, additional downside on the … Continue Reading
Read nowAMRN NCE Decision Remains Key; TEVA Potentially In The Race To Buy Is Surprising But Secondary
Most Popular - Thursday morning, Israeli financial newspaper, Calcalist is reporting that Teva Pharmaceuticals (NASDAQ:TEVA) and AstraZeneca (NYSE:AZN) are leading candidates among other large drug companies interested in … Continue Reading
Read nowPositive Naloxegol Results; NKTR Powering Through Analyst Downgrade
Long Ideas - Nektar Therapeutics (NASDAQ:NKTR) hosted a conference call Monday morning, highlighting the successful results from two Phase III trials and one safety extension study for Naloxegol, … Continue Reading
Read nowNo Launch Yet for AMRN’s Vascepa is Good News; NCE Decision Is The Next Key Event
Long Ideas - Earnings for Amarin Corp. (NASDAQ:AMRN) were primarily focused on the company’s strategy for the launch of Vascepa, as well as the FDA’s decision on whether … Continue Reading
Read nowMRGE Remains An Attractive Opportunity In Front Of Expected Private Equity Bids
Long Ideas - Merge Healthcare (NASDAQ:MRGE) is back in the news with Reuters reporting that the company’s plan to explore strategic alternatives has attracted at least five private … Continue Reading
Read nowPTN Succeeds In Key FSD Trial; Stock Has Room To Run
Long Ideas - Palatin Technologies (AMEX:PTN) announced this morning that its Phase IIb trial for bremelanotide met its primary endpoint, as well as secondary endpoints, for the treatment … Continue Reading
Read now